In this study, we examined stromal p16 expression in benign, precancerous, and malignant endometrial neoplasms using immunohistochemical staining and investigated whether a significant difference exists in stromal p16 immunoreactivity according to the degree of malignancy and/or histological type. This evidence concerns the gene CDKN2A and endometrium neoplasm.